We are live on ! Find out more
IMGN

Immunogen Inc
IMGN

Delisted

IMGN was delisted on the 9th of February, 2024.

Back to rankings

157 hedge funds and large institutions have $542M invested in Immunogen Inc in 2017 Q2 according to their latest regulatory filings, with 32 funds opening new positions, 42 increasing their positions, 46 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

256% more first-time investments, than exits

New positions opened: 32 | Existing positions closed: 9

155% more call options, than puts

Call options by funds: $4.33M | Put options by funds: $1.7M

107% more capital invested

Capital invested by funds: $262M → $542M (+$280M)

16% more funds holding

Funds holding: 135 → 157 (+22)

9% less repeat investments, than reductions

Existing positions increased: 42 | Existing positions reduced: 46

Holders
157
Holders Change
+22
Holders Change %
+16.3%
% of All Funds
3.91%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
32
Increased
42
Reduced
46
Closed
9
Calls
$4.33M
Puts
$1.7M
Net Calls
+$2.63M
Net Calls Change
+$2.96M

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$22M
2
Millennium Management
Millennium Management
New York
+$13.4M
3
State Street
State Street
Massachusetts
+$11.6M
4
RG
Redmile Group
California
+$5.62M
5
EI
EAM Investors
California
+$2.67M

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$9.87M
2
ClearBridge Investments
ClearBridge Investments
New York
-$7.13M
3
Norges Bank
Norges Bank
Norway
-$5.48M
4
Deutsche Bank
Deutsche Bank
Germany
-$3.65M
5
Renaissance Technologies
Renaissance Technologies
New York
-$3.46M
Name Holding Trade Value Shares
Change 		Change in
Stake
RJA
26
Raymond James & Associates
Florida
$3.9M -$368K -80,319 -13%
FCM
27
Farallon Capital Management
California
$3.59M +$2.31M +505,000 New
Jacobs Levy Equity Management
28
Jacobs Levy Equity Management
New Jersey
$2.49M +$1.6M +350,634 New
Invesco
29
Invesco
Georgia
$2.39M +$1.48M +323,366 +2,522%
Norges Bank
30
Norges Bank
Norway
$2.38M -$5.48M -1,196,793 -78%
Charles Schwab
31
Charles Schwab
California
$2.36M +$8.78K +1,919 +0.6%
Axa
32
Axa
France
$2.19M +$1.18M +256,900 +505%
Natixis Advisors
33
Natixis Advisors
Massachusetts
$2.08M -$33.7K -7,368 -2%
Fisher Asset Management
34
Fisher Asset Management
Washington
$1.82M +$11.6K +2,530 +1%
TCIM
35
TIAA CREF Investment Management
New York
$1.79M +$35K +7,658 +3%
Citigroup
36
Citigroup
New York
$1.73M +$643K +140,433 +136%
PC
37
Paulson & Co
New York
$1.63M +$1.05M +229,222 New
FIM
38
Fernwood Investment Management
Massachusetts
$1.55M +$1,000K +218,500 New
Ameriprise
39
Ameriprise
Minnesota
$1.55M -$807K -176,377 -45%
CEP
40
Chicago Equity Partners
Illinois
$1.55M +$999K +218,320 New
Royal Bank of Canada
41
Royal Bank of Canada
Ontario, Canada
$1.1M +$627K +137,061 +789%
TA
42
Teachers Advisors
New York
$1.1M -$162K -35,413 -19%
California State Teachers Retirement System (CalSTRS)
43
California State Teachers Retirement System (CalSTRS)
California
$1.06M -$76.9K -16,800 -10%
GCP
44
GSA Capital Partners
United Kingdom
$985K +$243K +53,000 +62%
Swiss National Bank
45
Swiss National Bank
Switzerland
$983K -$97K -21,200 -13%
Federated Hermes
46
Federated Hermes
Pennsylvania
$981K +$515K +112,525 +441%
CS
47
Credit Suisse
Switzerland
$917K +$254K +55,413 +75%
AQR Capital Management
48
AQR Capital Management
Connecticut
$905K +$582K +127,274 New
UBS Group
49
UBS Group
Switzerland
$881K +$109K +23,897 +24%
Russell Investments Group
50
Russell Investments Group
United Kingdom
$872K +$561K +122,621 New
1
2
3 4 5

IMGN Hedge Fund Activity: Q2 2017 in Review

157 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Immunogen Inc (IMGN) for Q2 2017, worth a combined $542M — up 107% from $262M a quarter earlier.

Buyers outnumbered sellers: 32 funds opened new IMGN positions and 9 closed out — a net gain of 23 holders — while 42 added to existing stakes and 46 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $22M. The largest seller was OrbiMed, cutting an estimated $9.87M.

  • 157 institutional investors held Immunogen Inc (IMGN) as of Q2 2017, up from 135 in Q1 2017.
  • Funds reported $542M of Immunogen Inc stock for Q2 2017, up 107% quarter-over-quarter.
  • 32 funds opened new Immunogen Inc positions in Q2 2017 and 9 closed out, a net change of +23 holders.
  • The largest Immunogen Inc buyer in Q2 2017 was Fidelity Investments, an estimated $22M added.
  • The largest Immunogen Inc seller in Q2 2017 was OrbiMed, an estimated $9.87M sold.

Based on aggregated 13F filings for Q2 2017.